1. BiomX raised $3 million through a private placement funding. 2. Series Y Convertible Preferred Stock offers 15% annual dividend, convertible to common stock. 3. Net proceeds will enhance bacteriophage program opportunities and corporate flexibility. 4. Warrants for 3.3 million shares suggest potential interest in stock performance. 5. Closing subject to typical conditions; stakeholders await pending approvals.
FAQ
Why Bullish?
The private placement injects capital to foster growth, indicating investor confidence. Historically, recent capital raises in biotech often resulted in stock price upticks, evidencing similar investor sentiment.
How important is it?
The capital raise supports key programs, pivotal for investor outlook and share valuation. The successful execution of the private placement speaks to operational resilience, impacting stock perception positively.
Why Short Term?
Immediate financing allows BiomX to explore new opportunities quickly, likely influencing short-term stock performance positively. Past placements in clinical biotech frequently result in price reactions in subsequent days.
BiomX (PHGE) Announces $3.0 Million Private Placement Financing
Company Overview and Financial Highlights
On December 29, 2025, BiomX Inc. (NYSE American: PHGE) announced that it has secured a private investment in public equity (PIPE) financing, with expected gross proceeds of approximately $3.0 million. The proceeds are before the deduction of placement agent fees and associated offering expenses. The exclusive placement agent for this private placement was H.C. Wainwright & Co..
Details of the Private Placement
Under the terms of the Private Placement, BiomX will issue shares of its Series Y Convertible Preferred Stock, valued at $1,000 per share. This offering will also include warrants with a combined stated value of up to $3.3 million. The total investment amount is set at $3.0 million.
- Dividend Rate: 15% per annum, payable quarterly
- Maturity Period: One year from closing date
- Conversion: Convertible into shares of the company's common stock
- Warrants: Up to 3,300,000 shares available at an initial exercise price of $2.00
Expected Closing and Usage of Proceeds
The Private Placement is expected to close on or around December 30, 2025, pending customary closing conditions. The securities offered in this placement have not been registered under the Securities Act of 1933 or any state securities laws, relying on exemptions from the registration requirements.
BiomX intends to utilize the net proceeds from this offering to enhance opportunities across its bacteriophage programs, including developing treatments for Staphylococcus aureus infections linked with diabetic foot ulcers, along with general corporate purposes for operational flexibility amid ongoing evaluations of strategic alternatives.
About BiomX and Its Innovative Approach
BiomX is at the forefront of developing natural and engineered phage therapies, which specifically target harmful bacteria contributing to chronic diseases. Through its proprietary “BacteriOphage Lead to Treatment” (BOLT) platform, BiomX customizes phage compositions to address these targeted bacteria effectively.
To learn more about the company's innovative solutions and strategic vision, visit www.biomx.com. Please note that the content on the website does not form part of this press release.
Forward-Looking Statements and Risk Factors
This announcement contains forward-looking statements that can be identified by terminology such as “believe,” “expect,” “will,” and similar expressions. These statements correspond to future events, trends, or expectations, which may not materialize as anticipated.
Investors are encouraged to review potential risks associated with the company’s activities, including regulatory approvals and market conditions, as detailed in BiomX’s Annual Report on Form 10-K and other public filings accessible through the SEC website at www.sec.gov.